population pharmacokinetic
Population Pharmacokinetic properties of Sulfadoxine and Pyrimethamine: A pooled analysis to Inform Optimal Dosing in African Children with Uncomplicated Malaria
... Population Pharmacokinetic properties of Sulfadoxine and Pyrimethamine A pooled analysis to Inform Optimal Dosing in African Children with Uncomplicated Malaria 1 Population Pharmacokinetic properties[.] ...
34
Tigecycline in critically ill patients on continuous renal replacement therapy: a population pharmacokinetic study
... The effluent measurements were added to the model and resulted in an estimated dialysis clearance of 1.69 L/ h for CVVHD and 2.71 L/h for the CVVHDF method. The mean (±SD, interindividual variability) saturation ...
7
Population Pharmacokinetic Analysis of Tacrolimus in Adult Mexican Patients with Renal Transplant
... A population pharmacokinetic model of tacrolimus was developed in Mexican adult kidney transplant recipients and their typical population values for pharmacokinetic parameters were ...More ...
10
Population Pharmacokinetic Pharmacodynamic Modeling of Caffeine Using Visual Analogue Scales
... Caffeine is a commonly ingested psychoactive substance which affects alertness and cognition. A clinical study was conducted to determine the effect of orally ingested caffeine on visual analogue scale (VAS) responses in ...
11
Population pharmacokinetic properties of artemisinin in healthy male Vietnamese volunteers
... In conclusion, this is the first population pharmacokinetic characterization of artemisinin in healthy volunteers. The highly informative dense sampling resulted in a one- compartment disposition model with ...
10
PKreport: report generation for checking population pharmacokinetic model assumptions
... The application of population pharmacokinetic (PopPK) modeling in the drug development has grown in this decade. It has numerous advantages over non-compart- mental analysis: incorporating unbalanced ...
10
The Influence of Normalization Weight in Population Pharmacokinetic Covariate Models
... estimates is increased (Table 1). This suggests that nor- malization affects the stability of the parameter estimation process, which has been described for both linear models, as well as population ...
8
Optimal designs for population pharmacokinetic studies of oral artesunate in patients with uncomplicated falciparum malaria
... Currently, population pharmacokinetic (PK) studies of anti-malarial drugs are designed primarily by the logistical and ethical constraints of taking blood samples from patients, and the statistical models ...
9
A population pharmacokinetic model incorporating saturable pharmacokinetics and autoinduction for high rifampicin doses
... final population pharmacokinetic model included an enzyme turnover model accounting for time-dependent elimination due to autoinduction, concentration-dependent clearance, and dose-dependent ...
10
Population pharmacokinetic modeling of the Qishe pill in three major traditional Chinese medicine defined constitutional types of healthy Chinese subjects: study protocol for a randomized controlled trial
... of population properties (age, gender, weight, constitutional type, history of disease and life style, ...the population pharmacokinetics (PopPK) of the Qishe pill in Chinese subjects should be ...the ...
10
Diagnostics for nonlinear models with application to population pharmacokinetic modeling
... Karlsson and Savic, 2007; Ene I. Ette, 2007). In the field of pharmacokinetics, many multi- dimensional data are generated to address various biological questions. Ette (1998) gives a comprehensive tutorial on applying ...
187
Population Pharmacokinetic Modeling of Acetaminophen and Metabolites in Children After Cardiac Surgery With Cardiopulmonary Bypass
... current (younger) patient population. In our model, all parameters were estimated with high accuracy and the same set of model parameters could be used to predict acetaminophen and metabolite concentrations ...
10
Towards Rational Dosing Algorithms for Vancomycin in Neonates and Infants Based on Population Pharmacokinetic Modeling
... versus population predicted concentrations (b and e) for the neonatal model (black dots, preterm neonates; gray dots, term neonates) and the pediatric model (black dots, postnatal age of ⬍ 31 days; gray dots, ...
9
Predicting tacrolimus concentrations in children receiving a heart transplant using a population pharmacokinetic model
... The population PK model identifies some of the causes of tacrolimus variability in paediatric heart transplant recipients, namely patient age, renal function and comedications that impact tacrolimus metabolism, ...
8
A population pharmacokinetic model of piperaquine in pregnant and non pregnant women with uncomplicated Plasmodium falciparum malaria in Sudan
... i th patient on the j th dose occasion, κ is the deviation from the population mean after each dose occasion, taken from a normal distribution with variance Π 2 and zero mean. An additive residual error model was ...
12
Glibenclamide population pharmacokinetic/pharmacodynamic modeling in South African type 2 diabetic subjects
... Patients and methods: A total of 24 type 2 diabetic patients participated in a glibenclamide dose-escalation study during which glibenclamide, glucose, and insulin concentrations were quantified, while the dose of ...
13
Population pharmacokinetic analysis and dosing regimen optimization of penicillin G in patients with infective endocarditis
... that population-based parameters are useful for evaluating penicillin G pharmacokinetics and that an individualized dosage should be determined based on a described dosage ...
8
Pharmacokinetics of meropenem in septic patients on sustained low efficiency dialysis: a population pharmacokinetic study
... Prospective population PK study on 19 septic patients treated with meropenem and receiving SLED for acute kidney ...Nonparametric population PK analysis with Monte Carlo simulations were ...
10
<p>Population pharmacokinetic modeling to facilitate dose selection of tapentadol in the pediatric population</p>
... Simulations were performed to determine the optimal dose of tapentadol in pediatric patients from 2 to <18 years. Table 3 and Figure 4 present the exposure distributions for the three age groups for three different ...
16
Mimicking in vivo exposures to drug combinations in vitro : anti tuberculosis drugs in lung lesions and the hollow fiber model of infection
... In-vitro pharmacokinetic profiles for lung lesion homogenate generated in the hollow fiber system fell within the intervals predicted by the population pharmacokinetic models taking into account ...
8